An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!
The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019.
:max_bytes(150000):strip_icc()/giraffe-standing-on-grassy-field-against-city-894690770-5ae9d01543a10300360255f8.jpg)
The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.
Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.
Page 2 of 7
NEWS
-
The Utility of a Two-Dose Ebola Vaccine Regimen Confirmed
In response to the 2014-2016 Ebola epidemic, the clinical development of a two-dose regimen of...
-
8th EBOVAC2 Newsletter
The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission...
-
European Commission Approval for Janssen’s Ebola vaccine regimen
Johnson & Johnson announced on 1st July 2020 that the European Commission (EC) has granted...
-
Positive CHMP Opinion for Janssen's Ebola Vaccine Regimen
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola...
-
Ebovac2 at ECCMID 2019
An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the...
-
Ebola: background
What is Ebola?
-
Phase 2 trials
Find out more about EBOVAC2 trials
-
Work programme
EBOVAC2 is organised into 6 workpackages (WP)
-
Ebola+ programme
Contributes to efforts to tackle a wide range of challenges in Ebola research
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA